Wanfu Biotech announced that Peng Zhongxiong, the company's director and senior manager, plans to reduce his holdings by no more than 29,700 shares through centralized bidding, accounting for 0.0064% of the company's total share capital excluding the number of shares repurchased from the special account. The reduction period is January 22, 2026 to April 21, 2026, with no reduction in holdings during the window; currently, it holds 118,900 shares, accounting for 0.025%. The proposed reduction price will be determined according to the secondary market price at that time. The reason for the reduction is personal capital requirements.

Wanfu Biotech announced that Peng Zhongxiong, the company's director and senior manager, plans to reduce his holdings by no more than 29,700 shares through centralized bidding, accounting for 0.0064% of the company's total share capital excluding the number of shares repurchased from the special account. The reduction period is January 22, 2026 to April 21, 2026, with no reduction in holdings during the window; currently, it holds 118,900 shares, accounting for 0.025%. The proposed reduction price will be determined according to the secondary market price at that time. The reason for the reduction is personal capital requirements.